Cutaneous Adverse Effects of EGFR Therapy in Breast Cancer Treatment

EGFR inhibitors used in breast cancer treatment can cause significant cutaneous adverse effects, such as alopecia, rashes, and severe conditions like Stevens-Johnson syndrome, impacting patients' quality of life and treatment compliance. The review of 73 studies from 1,498 articles highlights that these skin toxicities are dose-dependent, influenced by genetic and ethnic factors, and can lead to treatment modifications. Management strategies include prophylactic measures, symptomatic treatments, and emerging therapies like recombinant EGF ointments. The document emphasizes the need for personalized therapeutic management and further research to understand the molecular mechanisms and psychosocial effects of these toxicities, aiming to optimize treatment outcomes and improve patient care.